UBS Group
RYTM icon

UBS Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

UBS Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,100
Closed -$429K – 10763
2025
Q1 		$429K Buy
+8,100
New +$449K ﹤0.01% 5968

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group's RYTM Position: Q2 2026 in Review

UBS Group reduced its Rhythm Pharmaceuticals (RYTM) stake by 38% in Q2 2026, selling an estimated $7.89M and leaving 144,378 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2922.

UBS Group first reported a position in RYTM in Q4 2017 and has held it in 35 quarters since. The position peaked at $45.7M in Q4 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • UBS Group held 144,378 shares of Rhythm Pharmaceuticals worth $16M as of Q2 2026.
  • UBS Group sold 87,272 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $7.89M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2922 holding.
  • UBS Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
  • UBS Group's Rhythm Pharmaceuticals position peaked at $45.7M in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.